JP2014240385A5 - - Google Patents

Download PDF

Info

Publication number
JP2014240385A5
JP2014240385A5 JP2014115617A JP2014115617A JP2014240385A5 JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5 JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5
Authority
JP
Japan
Prior art keywords
mab
fgfr2iiic
inhibits
fgfr2iiib
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014115617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014240385A (ja
JP6342223B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014240385A publication Critical patent/JP2014240385A/ja
Publication of JP2014240385A5 publication Critical patent/JP2014240385A5/ja
Application granted granted Critical
Publication of JP6342223B2 publication Critical patent/JP6342223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014115617A 2008-11-07 2014-06-04 線維芽増殖因子受容体２に対するモノクローナル抗体 Active JP6342223B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US61/112,686 2008-11-07
US16487009P 2009-03-30 2009-03-30
US61/164,870 2009-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011534932A Division JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152670A Division JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2014240385A JP2014240385A (ja) 2014-12-25
JP2014240385A5 true JP2014240385A5 (enExample) 2015-02-12
JP6342223B2 JP6342223B2 (ja) 2018-06-13

Family

ID=42153600

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2011534932A Active JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2014115617A Active JP6342223B2 (ja) 2008-11-07 2014-06-04 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2016152670A Active JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2018223183A Active JP6661734B2 (ja) 2008-11-07 2018-11-29 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2020018719A Active JP6960485B2 (ja) 2008-11-07 2020-02-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2021166672A Active JP7301106B2 (ja) 2008-11-07 2021-10-11 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2023100475A Pending JP2023116746A (ja) 2008-11-07 2023-06-20 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2024193584A Pending JP2025032085A (ja) 2008-11-07 2024-11-05 線維芽増殖因子受容体２に対するモノクローナル抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011534932A Active JP5627591B2 (ja) 2008-11-07 2009-11-06 線維芽増殖因子受容体２に対するモノクローナル抗体

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016152670A Active JP6445496B2 (ja) 2008-11-07 2016-08-03 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2018223183A Active JP6661734B2 (ja) 2008-11-07 2018-11-29 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2020018719A Active JP6960485B2 (ja) 2008-11-07 2020-02-06 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2021166672A Active JP7301106B2 (ja) 2008-11-07 2021-10-11 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2023100475A Pending JP2023116746A (ja) 2008-11-07 2023-06-20 線維芽増殖因子受容体２に対するモノクローナル抗体
JP2024193584A Pending JP2025032085A (ja) 2008-11-07 2024-11-05 線維芽増殖因子受容体２に対するモノクローナル抗体

Country Status (20)

Country Link
US (8) US8101723B2 (enExample)
EP (4) EP2365828B1 (enExample)
JP (8) JP5627591B2 (enExample)
KR (1) KR101699432B1 (enExample)
CN (1) CN102131524B (enExample)
AU (1) AU2009313357B2 (enExample)
BR (1) BRPI0917315B8 (enExample)
CA (2) CA2733668C (enExample)
DK (3) DK2842573T3 (enExample)
ES (3) ES2646168T3 (enExample)
HR (2) HRP20171640T1 (enExample)
HU (1) HUE035700T2 (enExample)
LT (2) LT3290052T (enExample)
MX (1) MX2011000455A (enExample)
NO (1) NO2842573T3 (enExample)
PL (3) PL3290052T3 (enExample)
PT (3) PT2842573T (enExample)
RU (1) RU2546254C9 (enExample)
SI (2) SI2842573T1 (enExample)
WO (1) WO2010054265A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
KR20130065665A (ko) 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
RU2014128467A (ru) * 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
KR102050615B1 (ko) * 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
BR112014025037A2 (pt) * 2012-04-09 2018-07-31 Daiichi Sankyo Company, Limited anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
SI2936153T1 (sl) * 2012-12-21 2019-02-28 Janssen Biotech, Inc. Občutljiv multipleksni imunski test za topen rastni faktor fibroblasta
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
PH12019501393B1 (en) * 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015053407A1 (ja) * 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
JPWO2016171107A1 (ja) 2015-04-20 2018-03-22 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
CN112804989A (zh) 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
KR20220119144A (ko) * 2019-12-24 2022-08-26 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 신규한 항fgfr2b 항체
JP7686000B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
WO2021247718A1 (en) * 2020-06-03 2021-12-09 The Broad Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
NZ797493A (en) 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
KR20230129456A (ko) * 2020-12-29 2023-09-08 선전 포워드 파머수티컬즈 코 엘티디 항-fgfr2 항체 및 이의 용도
US20250277041A1 (en) * 2021-10-08 2025-09-04 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
KR20250099773A (ko) * 2022-09-30 2025-07-02 3에이치 파머슈티컬즈 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2024240107A1 (zh) * 2023-05-19 2024-11-28 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2024255756A1 (zh) * 2023-06-13 2024-12-19 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
TW202547875A (zh) * 2024-05-09 2025-12-16 大陸商正大天晴藥業集團股份有限公司 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
JP2005530687A (ja) 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
EP1697420A2 (en) * 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2018442A2 (en) * 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008052796A1 (en) * 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
JP2010525301A (ja) * 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Similar Documents

Publication Publication Date Title
JP2014240385A5 (enExample)
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
EP4048309A4 (en) HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
JP2013198490A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP2014205674A5 (enExample)
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
DK3389699T5 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
EP4032550A3 (en) Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
MX2015004105A (es) Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso.
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
JP2017506649A5 (enExample)
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9